Advanced Hepatocellular Carcinoma in Adults Without Cirrhosis: A Single-Institution Retrospective Review.
cirrhosis
hepatocellular carcinoma
non-cirrhotic
Journal
Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
08
2022
accepted:
22
10
2022
entrez:
26
12
2022
pubmed:
27
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Although up to one in five cases of hepatocellular carcinoma (HCC) occurs in patients without cirrhosis, there is scarce literature characterizing non-cirrhotic HCC (NCHCC). Existing NCHCC research is primarily limited to surgical case series and there is a lack of data on unresectable NCHCC. The purpose of this retrospective review was to compare the characteristics of unresectable NCHCC and cirrhotic hepatocellular carcinoma (CHCC). A retrospective chart review of adult patients with unresectable HCC treated from 2007 to 2017 was performed at the University of Florida Shands Hospital. The data set was stratified into two cohorts: NCHCC and CHCC. Continuous variables were compared using Wilcoxon-Mann-Whitney tests and Kruskal-Wallis rank-sum tests. Categorical variables were compared using Pearson's Chi-squared tests and Fisher's exact tests. Overall survival was explored utilizing the Kaplan-Meier and log-rank method. There were 1494 adult patients included in the final analysis, including 264 patients (17.7%) with NCHCC and 1230 patients (82.3%) with CHCC. Median age was 61.0 years old and median follow-up time was 30.2 months. NCHCC patients were older than CHCC patients (66.3 years vs 61.9 years; p < 0.0001). NHCC tumors were larger than CHCC tumors (7.92 ± 4.85 vs 4.38 ± 3.12 cm; p < 0.0001) and more likely to be associated with distant metastases (23.35% vs 15.91%; p = 0.0055). There was no difference in overall survival, with a median of 23.5 months in NCHCC and 22.4 months in CHCC (p = 0.9196). Our findings suggest that unresectable NCHCC and CHCC have unique characteristics but similar overall survival. To the best of our knowledge, this is the largest comparison of CHCC and NCHCC.
Sections du résumé
Background
UNASSIGNED
Although up to one in five cases of hepatocellular carcinoma (HCC) occurs in patients without cirrhosis, there is scarce literature characterizing non-cirrhotic HCC (NCHCC). Existing NCHCC research is primarily limited to surgical case series and there is a lack of data on unresectable NCHCC.
Aim
UNASSIGNED
The purpose of this retrospective review was to compare the characteristics of unresectable NCHCC and cirrhotic hepatocellular carcinoma (CHCC).
Methods
UNASSIGNED
A retrospective chart review of adult patients with unresectable HCC treated from 2007 to 2017 was performed at the University of Florida Shands Hospital. The data set was stratified into two cohorts: NCHCC and CHCC. Continuous variables were compared using Wilcoxon-Mann-Whitney tests and Kruskal-Wallis rank-sum tests. Categorical variables were compared using Pearson's Chi-squared tests and Fisher's exact tests. Overall survival was explored utilizing the Kaplan-Meier and log-rank method.
Results
UNASSIGNED
There were 1494 adult patients included in the final analysis, including 264 patients (17.7%) with NCHCC and 1230 patients (82.3%) with CHCC. Median age was 61.0 years old and median follow-up time was 30.2 months. NCHCC patients were older than CHCC patients (66.3 years vs 61.9 years; p < 0.0001). NHCC tumors were larger than CHCC tumors (7.92 ± 4.85 vs 4.38 ± 3.12 cm; p < 0.0001) and more likely to be associated with distant metastases (23.35% vs 15.91%; p = 0.0055). There was no difference in overall survival, with a median of 23.5 months in NCHCC and 22.4 months in CHCC (p = 0.9196).
Conclusion
UNASSIGNED
Our findings suggest that unresectable NCHCC and CHCC have unique characteristics but similar overall survival. To the best of our knowledge, this is the largest comparison of CHCC and NCHCC.
Identifiants
pubmed: 36567797
doi: 10.2147/JHC.S384438
pii: 384438
pmc: PMC9784459
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1299-1307Informations de copyright
© 2022 Altshuler et al.
Déclaration de conflit d'intérêts
Dr Jesus C Fabregas is part of the institutional research for Ipsen, BMS, Merck, Pfizer, Genentech, and Natera, outside the submitted work. The authors have no other conflicts of interest to declare in this work.
Références
BMC Gastroenterol. 2014 Jul 03;14:117
pubmed: 24990270
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Biol Med. 2021 Oct 01;:
pubmed: 34591416
J Clin Gastroenterol. 2014 Mar;48(3):279-89
pubmed: 24045276
J Surg Oncol. 2008 Dec 1;98(7):505-9
pubmed: 18932235
Am J Clin Pathol. 1996 Jan;105(1):65-75
pubmed: 8561091
Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:119-29
pubmed: 12786623
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Transpl Int. 2021 May;34(5):954-963
pubmed: 33660346
Eur J Gastroenterol Hepatol. 2016 Mar;28(3):352-9
pubmed: 26629867
Scand J Gastroenterol. 2012 Jun;47(6):718-28
pubmed: 22472070
Cancer. 1988 Oct 1;62(7):1414-24
pubmed: 2843280
J Hepatol. 2012 Aug;57(2):297-305
pubmed: 22521348
AJR Am J Roentgenol. 2014 Jul;203(1):W34-47
pubmed: 24951228
Eur J Radiol. 2017 Oct;95:349-361
pubmed: 28987692
World J Hepatol. 2019 Jan 27;11(1):1-18
pubmed: 30705715
Cancer Radiother. 2005 Nov;9(6-7):458-63
pubmed: 16223596
Dig Liver Dis. 2013 Feb;45(2):164-9
pubmed: 23047000
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
World J Gastroenterol. 2021 Jun 28;27(24):3466-3482
pubmed: 34239263